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Poster Session-II 151of drug, alcohol, or tobacco use; caregiver concerns; psychiatric di-
agnosis; a patient history of no-compliance; the stress of this intense
treatment option becomes escalated for all involved. Such factors can
lead to complications during the transplant course including longer
hospital stays, increased stress to the patient, caregiver, and health-
care team, increase ethical issues, and subsequent poorer outcomes.
Early identification of such factors permits development of a plan of
care to facilitate optimal treatment courses. The SCTNurse plays an
important role in identifying and addressing these issues.
Intervention: A quality improvement process was developed to
help identify confounding factors and address them prior to treat-
ment. An algorithm, including a multidisciplinary care conference
(CC), provides a process flow for the healthcare team to follow.
When an issue is identified by any member of the outpatient health-
care team, a CC is requested. Participants of CC include Physician,
APN, SocialWorker, Clinical Ethicist, Advocacy, and Clinic and In-
patient Nurse; with optional members including Adolescent Young
Adult, Psychiatry and Chaplaincy. The goal of the CC is to discuss
concerns with the patient, answer patient/caregivers questions, and
promote communication across the care continuum.
Results: The result of this process is the development of an indi-
vidualized plan of care that may include postponement of transplant,
substance abuse programparticipation, care contracts, and/or formal
ethics consult. A case study will be presented that highlights how the
use of this process has lead to improved patient outcomes. Recom-
mendations The implementation of this or a similar process in any
SCT program will help facilitate the proactive identification of con-
cerns and promote patients safely going forward with treatment.428
BLOOD AND MARROW TRANSPLANT TELEPHONE TRIAGE: DEVELOP-
MENT OF A DOCUMENTATION TOOL TO ASSIST WITH CONCISE INFOR-
MATION GATHERING
Ensley, L.A., Powell, S., Anderson-Reitz, L. Baylor Charles A Sammons
Cancer Center, Dallas, TX
Purpose/Background: Blood and marrow transplant patients
present complicated issues throughout the transplant process. Post
allograft patients can have complications long after the initial trans-
plant period. Out-patient transplant recipients often present acute
issues that may require admission to an in-patient setting. Registered
nurses are presented with the challenge of assessment and triage of
these complicated patients by telephone communication. The need
for a concise communication and documentation tool was identified
to assist with both information gathering and formulating amedically
directed plan.
Intervention: This center has a designated telephone line for pa-
tient ‘‘sick calls’’. Patients or caregivers are directed to utilize this line
for any medical issues. We have developed a tool specific to blood
and marrow transplant issues and complications. The tool helps
the registered nurse concisely collect and document information
provided by the patient or caregiver. This tool is then utilized to
communicate these issues to the medical staff for a medical plan
that is documented on the tool. The tool is currently being utilized
within a pilot period for six months.
Evaluation: The tool will be evaluated at the end of six months.
Additions or deletions will then bemade to the tool. Continued eval-
uation of the tool will then be made on a yearly basis.
Discussion: Utilization of a regimented documentation tool will
assist with prompting the nurse in phone assessment and triage and
will allow for more concise reporting to the medical staff and ulti-
mately better plans of care.429
ASSOCIATION OF HEMATOPOIETIC STEM CELL PRODUCT CULTURE AND
CLINICAL INFECTION IN PATIENTS RECEIVING MYELOABLATIVE CHE-
MOTHERAPYWITH AUTOLOGOUS HEMATOPOIETIC STEM CELL REINFU-
SION
Cervone, K., Cartwright, F., Gardner, S. NYU Medical Center, New
York, NY
Purpose: The purpose of this descriptive retrospective QA pro-
ject is to examine the association between hematopoietic progenitorcell (HPC) product cultures at the time of reinfusion and the subse-
quent development of infection.
Methods:Using a descriptive, retrospective design, data were col-
lected from the records of 68 patients who received autologous pe-
ripheral blood HPC reinfusions after undergoing myeloablative
chemotherapy at a single institution. Consistent with the oncology
service QA program, all of the products were tested for microbial
contamination at the time of stem cell processing. At the time of re-
infusion, a sample from each thawed product was sent to the micro-
biology lab. Following theHPC reinfusion, blood cultures were sent
on patients at the time of their first fever and at least once daily until
they were afebrile and cultures were negative. Blood cultures were
sent from each lumen of the central venous catheter. Peripheral
blood cultures were not routinely drawn.
Results: Between March 2002 and September 2008, 68 patients
received 148 HPC reinfusions. All of the reinfused HPC products
were negative for bacterial contamination at the time of processing.
Nineteen of the reinfused HPC cultures, which were reinfused into
13 patients, were positive. Two of these patients developed positive
blood cultures. Patient #1 had HPC product culture positive for
Bacillus species and Staphhylococcus epidermis. Blood cultures
were positive only for S. epidermis on day 115. Patient #2 had
HPC product cultures positive for Streptococcus oralis. Blood
cultures were positive for Streptococcus mitis on day 14 and S.
epidermis on day 16.
Conclusions: There does not appear to be a strong correlation
between positive product cultures and the subsequent development
of positve blood cultures. Microbial testing at the time of HPC
reinfusion may not be necessary.430
PNEUMOCYSTIS CARINII PNEUMONIA (PCP) PROPHYLAXIS PROTOCOL
AFTER AUTOLOGOUS TRANSPLANTS: A RETROSPECTIVE REVIEW AT A
REGIONAL TRANSPLANT CENTER
Ramey, S.1, Bohnenblust, E.1, Smalling, D.1, Schisler, N.1,
Thompson, L.1, Schammel, C.1, Dillard, T.2, Fanning, S.2, Webb, S.2
1Furman University, Greenville, SC; 2Cancer Centers of The Carolinas,
Greenville, SC
Autologous hematopoeitic stem cell transplantion is an effective
treatment option for many hematological diseases. The morbidity
associated with this treatment, however, is often related to the in-
creased risk of infection following transplant due to an immunocom-
promised host. Prophylactic care designed to prevent infection varies
widely among institutions. In this retrospective analysis, we reviewed
the prophylactic protocol for Pneumocystis carinii pneumonia (PCP)
at Cancer Centers of the Carolinas (CCC), a regional transplant cen-
ter. All autologous hematopoietic stem cell transplants completed
for hematologic disorders between 2002 and 2007 (n 5 150) were
reviewed with regard to prophylactic Bactrim administration. The
standard operating procedure at CCC utilized Bactrim at a dose of
one double strength tab BID on Saturday and Sunday each week.
Protocol guidelines suggest prophylactic Bactrim initiation fourteen
days post transplant, continuing minimally through day 1200. At
day 200, the peripheral blood CD4 count was assessed. A CD4 count
of .200 cells/mliter prompted Bactrim discontinuation. Per proto-
col, values lower than this threshold necessitated CD4 count reas-
sessment at 100-day intervals until the threshold was achieved.
Results revealed 69% of patients were tested to threshold while
28% of patients were not tested to threshold. Of patients who
reached threshold, 76% had done so by d1260. The median 200
day post-transplant CD4 count assessed was 232 cells/mliter. The
number of days to reach threshold was not significantly different
when considering gender, race, or primary disease. However,
patients with multiple myeloma requiring tandem transplantion re-
sulted in significant delays in reaching threshold with non-tandem
patients reaching threshold in a median time of 200 days and tandem
patients reaching threshold in a median time of 282 days. These
results verify that, per protocol, d1200 is a valid point to initiate
assessment of CD4 count recovery following single autologous
transplantion. Patients having reached the threshold at this time
can discontinue Bactrim prophylaxis, and thus eliminate any
potential for Bactrim-associated side effects. Patients with CD4
counts below threshold at initial testing remain at risk for PCP
